Securities Code: 002424 Securities Abbreviation: ST Bailin Announcement No.: 2026-024
Guizhou BaiLing Pharmaceutical Group Co., Ltd. Announcement on the Proposed Re-appointment of 2026 Financial and Internal Control Audit Institutions
The Company and all members of the Board of Directors guarantee that the information disclosed is true, accurate, and complete, and that there are no false records, misleading statements, or material omissions.
Special Reminder: Tianjian Certified Public Accountants (Special General Partnership) issued a qualified audit report with an emphasis of matter for the year 2025. The proposed re-appointment of Tianjian Certified Public Accountants (Special General Partnership) complies with the "Administrative Measures for the Selection of Accounting Firms by State-owned Enterprises and Listed Companies" (Cai Kuai [2023] No. 4) issued by the Ministry of Finance, the State-owned Assets Supervision and Administration Commission of the State Council, and the China Securities Regulatory Commission. The Company's Board of Directors reminds investors to invest cautiously and be aware of investment risks.
Guizhou BaiLing Pharmaceutical Group Co., Ltd. (hereinafter referred to as the "Company") held the 25th meeting of the Sixth Board of Directors on April 27, 2026, and reviewed and approved the "Proposal on the Proposed Re-appointment of 2026 Financial and Internal Control Audit Institutions." The Company proposes to re-appoint Tianjian Certified Public Accountants (Special General Partnership) (hereinafter referred to as "Tianjian Certified Public Accountants") as the financial and internal control audit institution for 2026. This matter still needs to be submitted to the Company's shareholders' meeting for approval. The relevant situation is hereby announced as follows: